MedPath

A study to determine the change in serum periostin level over 12 weeks in adult patients following a severe exacerbation of asthma

Not Applicable
Completed
Conditions
Periostin levels, in asthmatics following an exacerbation of their asthma
Respiratory - Asthma
Registration Number
ACTRN12614000443695
Lead Sponsor
Medical Research Institute of New Zealand
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
34
Inclusion Criteria

Aged between 18 to 75 years
Able to provide written informed consent
Doctor diagnosis of asthma
Exacerbation of asthma, defined as one or both of the following criteria:
Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days. For consistency, courses of corticosteroids separated by 1 week or more should be treated as separate severe exacerbations.
A hospitalization or Emergency Department visit because of asthma, requiring systemic corticosteroids. requiring admission to hospital
Participants prescribed a dose of systemic corticosteroids for at least 3 days will be eligible for the study, though it is recognised they will not have taken systemic corticosteroids for 3 days at the point of enrolment. Participants will not be eligible if they have commenced systemic corticosteroids greater than 24 hours prior to enrolment.
Participants who have increased from their stable maintenance dose of systemic corticosteroids will only be eligible if this dose increase is confirmed to be less than 24 hours prior to enrolment.

Exclusion Criteria

Known Pregnancy
Significant co morbidities (determined at investigator discretion)
Hospital admission within last 3 months for condition other than asthma
Surgery within last 3 months, determined at investigator discretion (this includes all major surgery requiring general anaesthetic, dental extractions and root canal procedures. This does not include minor procedures, including but not limited to mole or wart removal, dental fillings etc).
Bone fracture within the last 3 month
Any other safety concern at the investigator’s discretion

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath